Neuravi affirms its continued commitment to clot research and innovation in acute ischemic stroke at LINNC, Paris
LINNC Paris celebrated its 20th anniversary with extraordinary technical innovations in continuing medical education. Now a part of the Johnson & Johnson family of medical device companies, Neuravi worked alongside Codman Neurovascular unified in the goal of improving both ischemic and hemorrhagic stroke treatment.
Neuravi Thromboembolic Initiative Hosts Neurointervention Workshops at ESOC 2017
Neuravi shared research findings at Neurointervention Workshop sessions held at the 3rd European Stroke Organisation Conference in Prague. These workshops were hosted by Dr. Patrick Brouwer and Clinical R&D Engineer, Gillian Gunning, PhD. For the third successful year at ESOC, clinical leaders in stroke, scientists, and engineers gathered to share research and discuss the clots and occlusions causing acute ischemic stroke.
Sharon Duffy, Postgraduate Researcher at Neuravi, also showcased clot research in the poster presentation at ESOC 2017 on ‘Changes in clot properties from exposure to recombinant Tissue Plasminogen Activator and possible implications for mechanical thrombectomy in acute ischemic stroke’.
Neuravi Thromboembolic Initiative Supports WLNC in Los Angeles
Neuravi was honored to be invited to present at the World Live Neurovascular Conference in Los Angeles. Mahmood Mirza, Senior Clinical R&D Engineer, presented NTI insights into the significance of clot properties in Mechanical Thrombectomy.
International Thought Leaders Gather for Clot Summit 2016
For the second year, clinical leaders in stroke, scientists and engineers gathered to share research related to more fully understanding the clots and occlusions causing acute ischemic stroke. Co-chaired by Prof. Werner Hacke and Dr. David Liebeskind, the summit featured thought-provoking discussions on the state of clot knowledge thus far, further research needed, and how to integrate this into advancing stroke therapy.
Neuravi Sponsors Educational Science of Clot Workshops at SVIN 2016
In collaboration with the SVIN, the NTI presented interactive workshops analyzing the clots that cause large vessel occlusions. Attendees and engineers exchanged insights from in vitro and in vivo testing and from clinical experience. NTI research as well as findings from collaborative research projects were shared.
During the SVIN scientific sessions, David Vale was honored to be invited to present an engineering analysis of the thrombus that causes Large Vessel Occlusions, elaborating on some of the most recent NTI research.
Neuravi Hosts Hands-On Sessions at ESMINT 2016
September’s ESMINT meeting in NICE featured the inaugural symposium for nurses, technicians and radiographers. In support of this, the NTI suite shared research on the occlusions that cause stroke and provided the opportunity for hands-on use of the EmboTrap Revascularization Device in a vascular model for the nurses and technicians participating in the workshop.
Neuravi Holds NTI Clot Sessions at SNIS 2016
At the recent SNIS meeting in Boston, Neuravi set up an NTI Suite and held discussions with clinicians regarding engineering and clinical perspectives on clot properties, their behavior, and the implications for thrombectomy.
Mike Gilvarry Presents at LINNC 2016, Sharing an NTI Engineering Perspective on Thrombectomy Challenges
Mike Gilvarry, VP R&D and Technical Operations, was honored to be invited to present at LINNC 2016 on NTI clot research and the implications for stroke thrombectomy therapy.
Neuravi Thromboembolic Initiative Holds Clot Workshops at ESOC 2016
Neuravi shared clot research findings at both an ESMINT-ESO workshop session and during a “Science of Clot” pop-up workshop in May at the 2nd European Stroke Organisation Conference in Barcelona. Professor Laurent Pierot presented on some of the clinical challenges faced as in the continued quest for improved clinical outcomes, noting the importance of understanding clot in order to improve therapy.
Neuravi’s Partnerships in the Netherlands Recognized at Reception with Ireland’s Prime Minister Honoring Irish-Benelux Business Relations
Clot Summit 2015, Heidelberg, Germany
Istvan Szikora, MD; Urs Fischer, MD; Diederik Dippel, MD; Mairsil Claffey; Charles Majoie, MD; David Vale; Mike Gilvarry; Adnan Siddiqui, MD; Tudor Jovin, MD; Eamon Brady; Pooja Khatri, MD; Matt Gounis, PhD; Kennedy Lees, MD; Chloe Brown; Waleed Brinjikji, MD; Werner Hacke, MD; Blaise Baxter, MD; Rüdiger Von Kummer, MD; Andrew Demchuk, MD; Vincent Costalat, MD; David Liebeskind, MD; Bruce Campbell, MD; Patrick Brouwer, MD; Jill Amstutz; Paul Geudens; Olav Jansen, MD; Simon De Meyer, PhD; Tommy Andersson, MD, PhD
Not pictured: Martin Bendszus, MD; Antoni Dávalos, MD; Ana Paula Narata, MD; Raul Nogueira, MD; Peter Arthur Ringleb, MD
Neuravi Thromboembolic Initiative Hosts Hands-on Sessions at SNIS
Neuravi held a series of NTI sessions in July at the SNIS Annual Meeting to share its research on occlusion dynamics and clot properties with physicians. At an evening reception, Prof. Dr. Tommy Andersson presented his insights on the impact that both clot and technique can have on endovascular stroke intervention. The sessions were well attended and represented the first opportunity for Neuravi to share clot research in a meaningful way with US physicians.
Clot & Technique Matter – Insights for Endovascular Stroke Intervention
Tommy Andersson, MD, PhD
Professor of Neurointervention,
AZ Groeninge, Kortrijk, Belgium
Neuravi Thromboembolic Initiative Supports SLICE Course in Nice
Neuravi was honored to be invited to support the inaugural SLICE meeting in Nice in September. Our engineers worked closely with the course sponsors on occlusion modeling to support the Thrombus Lab. Using anatomical models and thrombus analogues, the course provided the unique opportunity for physicians to perform live in vitro demonstrations. VP of R&D, Mike Gilvarry, also shared learning from NTI clot research with those in attendance.
Neuravi Thromboembolic Initiative welcomed by the European Stroke Organisation
On April 17-19, The ESO held their first annual conference in Glasgow under the theme “The Voice of Stroke in Europe”. Nearly 2,700 delegates attended from 84 countries. Clinical results were presented from multiple trials, including the latest positive trials in mechanical thrombectomy. REVASCAT and SWIFT PRIME were presented to a packed auditorium by the respective study PI’s and were published simultaneously on-line. Sub-analyses from MR CLEAN, ESCAPE, EXTEND-IA and THRACE added to the overwhelmingly positive evidence of the benefit of endovascular therapy in the setting of large vessel occlusive ischemic stroke. In light of the compelling evidence for mechanical thrombectomy as the best treatment for large vessel occlusions, the discussion of current priorities emphasized the importance of getting patients into comprehensive stroke centers where they can get the best possible treatment. Other important factors in advancing stroke treatment include continued efforts in improving outcomes through procedural techniques as well as through technological advances.
At Saturday morning’s Neurointervention session, chaired by Prof. Gerhard Schroth and Prof. Andrew Demchuk, Michael Gilvarry, Neuravi VP of R&D, presented on clot research of relevance in acute stroke therapy. The presentation, entitled ‘CLOT PHYSICAL BEHAVIOUR IN ACUTE ISCHEMIC STROKE – IMPLICATIONS OF CLOT-DEVICE INTERACTION IN RECANALIZATION THERAPY’, provided insight in clot composition, categorization, occlusion formation, and physical behavior, all having an important impact on procedural planning, device selection and possible procedural outcomes.
Neuravi was honored to be invited to participate in the joint ESMINT-ESNR-ESO workshops on Endovascular Recanalisation. The NTI station, co-presented by neurointerventionalist Dr. Luisa Biscoito and Neuravi engineers, focused on clot morphology and physical properties, and included a hands-on experience that led to interactive discussion between the engineers and physicians. Attendees were then shown how the scientific insight in clot led to the development of the EmboTrap thrombectomy device.
“For our inaugural ESO conference, we felt it was very important to cover stroke therapy from multiple perspectives, which is why we coordinated the joint ESMINT-ESNR-ESO workshop sessions. The presentations by our interventional colleagues were quite compelling, and the hands-on portion deepened the understanding of what is involved in endovascular stroke intervention.” – Dr. Patrik Michel
“We were pleased to have Neuravi participate in the joint workshops and to share their clot research findings,” – Prof. Laurent Pierot, ESMINT General Secretary
Prof. Michael Söderman from Karolinska University Hospital in Stockholm, Sweden presented the poster ‘Initial Experience in 42 patients from 2 European Centers’. Results of this first in human experience showed that the EmboTrap was successful in achieving recanalization in 86% of patients with a TICI score ≥2b. 62% of patients in the overall series had a good clinical outcome (mRS 0-2 at 90 days). There were no device failures and the average time from first EmboTrap deployment to procedural completion was 9 mins 30 secs.
Neuravi Thromboembolic Initiative Introduced at ESMINT 2014
With the support of ESMINT, Neuravi introduced the Neuravi Thromboembolic Initiative through a series of interactive workshops during September’s ESMINT conference in Nice. Over 50 physicians visited the Neuravi Thromboembolic Initiative that brought together Neuravi engineers with clinicians from leading international institutions.
In his opening remarks, Dr. Anastasios Mpotsaris, Uniklinik Köln noted, “Core lab controlled studies show consistently that 25% of cases are not revascularized successfully, even in very experienced hands. We need to find out why.” He suggested that a better understanding of clot may help in addressing this challenge. Michael Gilvarry then shared Neuravi’s work recreating stroke scenarios using a range of clot analogues with varying composition and formation conditions. Physicians were able to observe differences in clot characteristics and behavior at a series of interactive workstations. The engineers explained how these models have enabled a depth of understanding in occlusion-device interaction, which has informed device development.
“What we’ve seen here today is that there are significant differences in how different clots and occlusions behave, which has implications for our technique and for device selection. I applaud the thoroughness of this research.” – Prof. István Szikora, President-elect of ESMINT
Dr. Olav Jansen observed – “We are committed to improving stroke therapy through our research on the bench and with advances in imaging – and this is the type of learning that complements our efforts. I wish we’d done this.”
Physicians with further interest in learning about the findings of the NTI and in exploring collaborative research may contact us at email@example.com. Keep an eye on the Events page of the web-site at www.neuravi.com for future NTI educational opportunities.